|
|
| Line 13: |
Line 13: |
| #*[[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]] | | #*[[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]] |
| #[[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]] | | #[[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]] |
|
| |
| ===[[Omega-3 fatty acids | Omega-3 Fatty Acids]]===
| |
|
| |
| {|class="wikitable" border="1" style="width:750px"
| |
| |-style="background:#CDC9C9"
| |
| |''' Drug '''
| |
| |''' Mechanisms of Benefit '''
| |
| |''' Dosage '''
| |
| |''' Advantages '''
| |
| |''' Side Effects '''
| |
| |''' Contraindications '''
| |
| |-
| |
| | '''Omega-3 fatty acids'''
| |
| |
| |
| ↓ hepatic [[lipogenesis]]<br>↓ plasma [[lipoprotein lipase]] activity<br>↑ hepatic mitochondrial and peroxisomal [[beta-oxidation]]<br>Inhibition of acyl CoA:1,2-[[diacylglycerol acyltransferase]] enzyme<br>[[EPA]] and [[DHA]] are poor enzyme substrates for [[triglyceride]] synthesis in [[liver]] and inhibits esterification of other fatty acids.
| |
| |
| |
| 3 g/day of EPA and DHA<ref name="pmid16825676">{{cite journal| author=Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B et al.| title=n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. | journal=Am J Clin Nutr | year= 2006 | volume= 84 | issue= 1 |pages= 5-17 | pmid=16825676 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16825676 }} </ref>
| |
| |
| |
| ↓ [[VLDL]]<ref name="pmid6736254">{{cite journal| author=Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R| title=Suppression by diets rich in fish oil of very low density lipoprotein production in man. | journal=J Clin Invest | year= 1984 | volume= 74 | issue= 1 | pages= 82-9 | pmid=6736254 | doi=10.1172/JCI111422 | pmc=PMC425187 | url=}} </ref>, <ref name="pmid11303007">{{cite journal| author=Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA et al.| title=An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. |journal=Heart | year= 2001 | volume= 85 | issue= 5 | pages= 544-8 | pmid=11303007 | doi= | pmc=PMC1729738 | url= }}</ref><br>↓ [[TG]] by ≥50%
| |
| |
| |
| [[Bleeding]], at high doses<br>
| |
| Fishy smell, can be reduced by
| |
| *freezing of medication
| |
| *trying different formulation
| |
| *taking medication with food
| |
| [[Nausea]]
| |
| |
| |
| Hypersensitivity
| |
| |} (↑ - Increase, ↓ - Decrease)
| |
|
| |
|
| ==References== | | ==References== |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hardik Patel, M.D.
Overview
Hyperlipidemia requires early detection, careful evaluation and aggressive treatment with combination of therapeutic lifestyle changes and lipid-lowering drug therapies to reduce the risk of cardiovascular and cerebrovascular complications.
Medical Therapy
Medical Therapy in Children and Adolescents
- Drug therapy
- Adjuvant therapies
References
Template:WH
Template:WS